The Prognostic Role of Late Gadolinium Enhancement in Aortic Stenosis A Systematic Review and Meta-Analysis

OBJECTIVES The aim of this systematic review was to explore the prognostic value of late gadolinium enhancement (LGE) in patients with aortic stenosis (AS). BACKGROUND Myocardial fibrosis is a common feature of many cardiac diseases. Cardiac magnetic resonance (CMR) has the ability to noninvasively...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JACC. Cardiovascular imaging 2020-02, Vol.13 (2), p.385-392
Hauptverfasser: Papanastasiou, Christos A., Kokkinidis, Damianos G., Kampaktsis, Polydoros N., Bikakis, Iosif, Cunha, Daniela K., Oikonomou, Evangelos K., Greenwood, John P., Garcia, Mario J., Karamitsos, Theodoros D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:OBJECTIVES The aim of this systematic review was to explore the prognostic value of late gadolinium enhancement (LGE) in patients with aortic stenosis (AS). BACKGROUND Myocardial fibrosis is a common feature of many cardiac diseases. Cardiac magnetic resonance (CMR) has the ability to noninvasively detect regional fibrosis by using the LGE technique. Several studies have explored whether LGE is associated with adverse outcome in patients with AS. METHODS Electronic databases were searched to identify studies investigating the ability of LGE to predict all-cause mortality in patients with AS. A random effects model meta-analysis was conducted. Heterogeneity was assessed with the I-2 statistic. RESULTS Six studies comprising 1,151 patients met our inclusion criteria. LGE was present in 49.1% of patients with AS. In the pooled analysis, LGE was found to be a strong univariate predictor of all-cause mortality (pooled unadjusted odds ratio: 2.56; 95% confidence interval: 1.83 to 3.57; I-2 = 0%). Four of the included studies reported adjusted hazard ratios for mortality. LGE was independently associated with mortality, even after adjusting for baseline characteristics (pooled adjusted hazard ratio: 2.50; 95% confidence interval: 1.64 to 3.83; I-2 = 0 %). CONCLUSIONS Fibrosis on LGE CMR is a powerful predictor of all-cause mortality in patients with AS and may serve as a novel marker for risk stratification. Future studies should explore whether LGE CMR can also be used to optimize timing of AS-related interventions. (C) 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation.
ISSN:1936-878X
1876-7591
DOI:10.1016/j.jcmg.2019.03.029